A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Company Comments on Consent Proposal; Provides Corporate UpdateNEW YORK, Aug. 8, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the...
NEW YORK, June 05, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company") announced today that its 2017 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The Annual...
NEW YORK, May 09, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2017. Highlights for the first quarter...
NEW YORK, April 27, 2017 -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
NEW YORK, April 18, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, commended Spire Southampton Hospital on the performance of over 100 percutaneous hepatic perfusion...
NEW YORK, March 29, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the 12 months ended December 31, 2016. Highlights for the fourth...
Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017 NEW YORK, March 27, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces...
NEW YORK, March 10, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of...
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months NEW YORK, Feb. 22, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers,...
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders NEW YORK, Feb. 21, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology...
NEW YORK, Jan. 23, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of...
NEW YORK, Jan. 18, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, today announced that new data from a retrospective study of Melphalan/HDS, entitled "Percutaneous...
Company Accepts Invitation from Cholangiocarcinoma Foundation to Present Initial Signals in ICCNEW YORK, Jan. 12, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers,...
NEW YORK, Nov. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three and nine months ended September 30, 2016. Highlights for the...
NEW YORK, Oct. 18, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
NEW YORK, Oct. 17, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a review of research conducted with the Delcath Hepatic CHEMOSAT® Delivery System...
NEW YORK, Oct. 12, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that five clinical sites in Europe have been activated and are open for patient enrollment...
NEW YORK, Oct. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that five new clinical trial sites in the U.S. have been activated in the Company's global...
NEW YORK, Oct. 5, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the Dawson James Securities Growth Stock...
NEW YORK - Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000 shares of its common stock at a price...
NEW YORK, Sept. 29, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to...
NEW YORK, Sept. 19, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on treatments for primary and metastatic liver cancers, announces that the company provided a grant to the Ocular Melanoma Foundation (OMF) in support of the...
Single-Institution Studies Add to Growing Body of Research Supporting CHEMOSAT for Treatment of Cancers of the Liver NEW YORK - Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on developing safe and effective treatments for primary and...
NEW YORK, Sept. 12, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Company management will participate at the 2016 Aegis Growth Conference taking place...
NEW YORK, Sept. 12, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that a research team led by Dr. Mark C. Burgmans at Leiden University Medical Center (LUMC)...
NEW YORK, Aug. 16, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six...
NEW YORK, July 18, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that abstracts from two studies conducted in...
NEW YORK, July 7, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that a review of clinical research treatment outcomes using Melphalan...
Unprecedented Progression Free and Overall Survival Observed in University Hospital Southampton Retrospective AnalysisNEW YORK, July 6, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on treatment of primary...
Againsttheodds.eu Recognized for High Quality Consumer Health ContentNEW YORK, June 23, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that the...
NEW YORK, June 15, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that data from a large single hospital...
Proceeds expected to fund operations through year-end 2017NEW YORK, June 7, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver...
NEW YORK, June 1, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the General and Digestive Surgery team...
NEW YORK, May 31, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at...
NEW YORK, May 4, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended...
NEW YORK, May 3, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that John Wayne Cancer Institute in Los Angeles, California and Duke Cancer...
Growing Adoption of CHEMOSAT Permits Expansion Outside of European UnionNEW YORK, April 8, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces...
Quarterly and yearly revenue grow more than 50% compared with 2014NEW YORK, March 21, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic...
NEW YORK, March 7, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at...
Distinguished Physician and Pharmaceutical Industry Executive to Serve as Senior Advisor for Clinical DevelopmentNEW YORK, Feb. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis...
NEW YORK, Feb. 10, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that patient enrollment has begun in the...
NEW YORK, Feb. 4, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate at...
Moffitt Cancer Center Begins Patient Enrollment in FOCUS Trial; Study Results to Support U.S. New Drug ApplicationNEW YORK, Jan. 20, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an...
Agreement Provides Regulatory Pathway for Melphalan/HDS with a Single Phase 3 Trial; Satisfies Substantial Number of Requirements in FDA's September 2013 Complete Response LetterNEW YORK, Jan. 19, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty...
NEW YORK, Jan. 15, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that Company management will participate in...
First Review of Current Product and Procedure to be used in the Planned Global Phase 3 TrialNEW YORK, Jan. 11, 2016 -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of...